PMGC Holdings (ELAB) Gross Margin (2022 - 2026)

PMGC Holdings' (ELAB) quarterly Gross Margin came in at 29.52% in Q2 2026, down 12.65% quarter-over-quarter from 33.79% in Q1 2026.

Analysis

PMGC Holdings (ELAB) Gross Margin (2022 - 2026) Analysis & Trends

PMGC Holdings has disclosed Gross Margin across 5 years of filings, most recently posting 29.52% for Q2 2026.

In Q2 2026, Gross Margin changed N/A year-over-year to 29.52%; the TTM figure through Jun 2026 stood at 29.38% (down 4450.0% YoY), while the FY2025 annual figure was 31.4%, down 4143.0% from the prior year.
Gross Margin came in at 29.52% for Q2 2026 at PMGC Holdings, down from 33.79% in the prior quarter.
In the past five years, Gross Margin ranged from a high of 79.96% in Q1 2025 to a low of 20.87% in Q4 2025.
Average Gross Margin over 5 years is 57.43%, with a median of 66.01% recorded in 2023.
Year-over-year, Gross Margin jumped 1101 bps in 2023 and sank 5115 bps in 2025.
Over 5 years, Gross Margin stood at 56.41% in 2022, then climbed by 17 bps to 66.09% in 2023, then rose by 9 bps to 72.01% in 2024, then plunged by 71 bps to 20.87% in 2025, then jumped by 41 bps to 29.52% in 2026.
Per Business Quant data, the three most recent Gross Margin figures were 29.52% in Q2 2026, 33.79% in Q1 2026, and 20.87% in Q4 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Amgen	207.26 Bn	193.27 Bn	7.24 Bn	72.04%
2	Gilead Sciences	179.66 Bn	176.48 Bn	6.22 Bn	79.76%
3	Vertex Pharmaceuticals	131.52 Bn	123.67 Bn	2.84 Bn	85.33%
4	Regeneron Pharmaceuticals	81.77 Bn	73.78 Bn	3.93 Bn	91.59%
5	Argenx Se	61.15 Bn	55.97 Bn	1.37 Bn	90.43%
6	Moderna	53.55 Bn	48.41 Bn	52.00 Mn	35.86%
7	Alnylam Pharmaceuticals	33.38 Bn	30.07 Bn	992.69 Mn	76.90%
8	Biogen	31.68 Bn	30.40 Bn	1.96 Bn	71.60%
9	Roivant Sciences	29.12 Bn	29.12 Bn	1.16 Mn	80.31%
10	PMGC Holdings	2.29 Mn	-16.50 Mn	385,691.00	29.52%

Historic Data

Download Data